For YMB readers:

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply

cheng_ho
Posts: 196
Joined: Sun Apr 03, 2016 11:27 pm

Re: For YMB readers:

Post by cheng_ho » Sat Dec 03, 2022 9:47 pm

Thanks. This poster doesn't seem to back up any SF3B1 limitations... in fact, it doesn't seem useful for further genetic targeting at all, which is unfortunate. Hopefully there is better data from the Phase 3.

Ryan
Posts: 184
Joined: Sat Jul 08, 2017 1:41 pm

Re: For YMB readers:

Post by Ryan » Sun Dec 04, 2022 1:25 am

I’d say the Conclusion is the best part. It’s pretty straight forward.

Per the yahoo ad naseau, I would point out these words:
“across different molecularly defined subgroups”

These words are preceded by “demonstrated clinical efficacy”.

Imetelstat demonstrated clinical efficacy across different molecularly defined subgroups of heavily transfused LR-MDS ESA-R/R patients, including those with poor prognosis, who have limited treatment options.

REFERENCES
1. Sperling AS, et al, Nat Rev Cancer 2017; 17(1): 5–19.
2. Gurkan E, et al , Leuk Res 2005; 29:1131-9.
3. Mittelman M, et al, Leukemia Research 34 (2010) 1551–1555. 4. Asai A, et al, Cancer Res 2003; 63(14):3931–3939.
5. Herbert BS, et al, Oncogene 2005; 24(33):5262–5268.
6. Mosoyan G et al. Leukemia 2017; 31(11):2458-2467
7. Wang X at al. Blood Adv 2018; 25;2(18):2378-2388
8. Steensma DP, et al, J Clin Oncol 2021; 39(1):48-56
9. Platzbecker U et al, ASH 2020 Oral presentation, Abstract #658

Post Reply